| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| α-Bisabolol — α-Bisabolol is a naturally occurring monocyclic sesquiterpene alcohol best known as a major bioactive constituent of chamomile essential oil, especially German chamomile (Matricaria chamomilla / Matricaria recutita) and related chamomile preparations. It is a small lipophilic phytochemical classified as a plant-derived essential-oil terpene alcohol, with common abbreviations including α-BSB, BSB, and levomenol for the (-)-α-bisabolol enantiomer. In oncology research it is mainly a preclinical pro-apoptotic and anti-invasive compound with preferential mitochondrial stress effects in cancer models; in clinical deployment it remains a cosmetic/natural-health constituent rather than an approved anticancer drug. -The main components in German chamomile are terpenoid; α-bisabolol and its oxide azulenes, such as chamazulene (1–15%); and apigenin. Roman chamomile, on the other hand, contains mainly angelic acid and tiglic acid esters. Apigenin is a main bioactive component and considered a quality marker of chamomile.Primary mechanisms (ranked):
Bioavailability / PK relevance: α-Bisabolol is highly lipophilic and poorly water soluble, so systemic translation depends strongly on formulation, route, dose, and vehicle. Essential-oil or neat-compound exposure does not imply predictable plasma exposure, and advanced delivery systems such as cyclodextrin complexes, nanoemulsions, or lipid carriers may be required for reproducible systemic or CNS delivery. In-vitro vs systemic exposure relevance: Most anticancer findings use direct in-vitro exposure at micromolar to high-micromolar concentrations, often with solvent-assisted delivery. These concentrations may exceed achievable free systemic exposure after ordinary chamomile tea, dietary chamomile, or topical/cosmetic use. Chamomile oil composition is also chemotype-dependent, so α-bisabolol content can vary substantially. Clinical evidence status: Cancer evidence is preclinical only. There are human trials of α-bisabolol-containing topical products for non-cancer indications, and chamomile has natural-health/traditional-use monographs for digestive, inflammatory gastrointestinal, and calmative uses, but there is no established human oncology indication, no approved anticancer label, and no cancer RCT evidence for α-bisabolol or chamomile oil. Mechanistic Profile
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Alzheimer’s disease relevance: α-Bisabolol has meaningful preclinical AD relevance through amyloid-β toxicity reduction, mitochondrial protection, anti-inflammatory activity, oxidative-stress reduction, and possible cholinesterase-related effects. Evidence includes Aβ-induced cell and animal/C. elegans models, scopolamine-memory models for α-bisabolol derivatives, and chamomile essential-oil studies with α-bisabolol-rich composition. However, there is no established human AD clinical evidence for α-bisabolol, and brain exposure is likely formulation-dependent because the compound is lipophilic and poorly water soluble. |
| Source: |
| Type: |
| PDK1 (3-phosphoinositide-dependent protein kinase-1) (PDPK1) is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell growth, survival, and metabolism. It is a key component of the PI3K/Akt signaling pathway, which is often dysregulated in cancer. Overexpression or hyperactivation of PDK1 can lead to increased cell proliferation, survival, and resistance to apoptosis, contributing to tumorigenesis. Inhibitors of PDK1 are being explored in preclinical and clinical studies as a means to disrupt cancer cell growth and survival. |
| 6547- | BSB, | Antitumor effects of a-bisabolol against pancreatic cancer |
| - | vitro+vivo, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | KLM1 | - | in-vitro, | PC, | KP4 | - | in-vitro, | Nor, | ACBRI515 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:413 Target#:246 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid